Loading...
Market
Impact of Sanofi's 340B program changes on hospital participation by end of 2024
2
Resolution / Starting Odds
Increased participation • 25%
Decreased participation • 25%
No change in participation • 25%
Insufficient data to determine • 25%
Surveys or reports from healthcare associations or industry analysis
Story
Sanofi to Revise U.S. 340B Drug Discount Program for Low-Income Hospitals Next Year
Nov 22, 2024, 09:05 PM
Sanofi, a French pharmaceutical company, is set to modify its approach to the U.S. 340B drug discount program, which provides discounts to hospitals serving low-income and uninsured patients. Starting next year, the company plans to require hospitals to submit detailed pharmacy and medical claims, including patient information, for review before receiving discounts. This move intensifies an industry fight against lucrative drug discounts for hospitals. Sanofi's decision follows similar actions by Johnson & Johnson and Eli Lilly, indicating a trend among major pharmaceutical companies to alter how they provide discounts under the 340B program.
View original story
Similar markets
None • 25%
1 company • 25%
2 companies • 25%
3 or more companies • 25%
No reduction • 33%
Up to 25% reduction • 33%
More than 25% reduction • 33%
Increase by less than 10% • 25%
Increase by 10% to 20% • 25%
Increase by 20% to 30% • 25%
Increase by more than 30% • 25%
Significant increase (>10%) • 25%
Moderate increase (0-10%) • 25%
No change or decrease • 25%
Significant decrease (>10%) • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Merck • 25%
Other • 25%
Comply Fully • 33%
Challenge in Court • 33%
Relocate Services • 34%
Significant positive impact • 25%
Moderate positive impact • 25%
No significant impact • 25%
Negative impact • 25%
Less than 5% increase • 25%
5% to 10% increase • 25%
10% to 15% increase • 25%
More than 15% increase • 25%
Increase by over 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change • 25%
Increase by more than 5% • 25%
Decrease by more than 5% • 25%
Remain roughly the same • 25%
Other • 25%
Significant increase in patient access • 25%
Moderate increase in patient access • 25%
No significant change in patient access • 25%
Decrease in patient access • 25%
0-5 partnerships • 33%
6-10 partnerships • 33%
More than 10 partnerships • 33%